Merck Animal Health’s $400 Million Acquisition of Rights to SENTINEL Parasiticides

The Baker Botts LLP and Paul Hastings LLP advised Merck Animal Health in the transaction.

Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), and Virbac (NYSE Euronext:VIRP) announced that the companies have signed a definitive agreement under which Merck Animal Health would acquire the U.S. rights to SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® Chews in the Companion Animal category. Merck Animal Health will make a cash payment of approximately $400 million to acquire the SENTINEL branded products in the United States at closing of the acquisition.

Comprehensive parasite protection is an essential part of canine overall health and well-being. The BRAVECTO® product line, which are our extended duration flea and tick protection products, and the SENTINEL branded products, which control all common intestinal parasites, provide an attractive opportunity for broad-spectrum, year-round comprehensive internal and external parasite protection for dogs. These complementary products will cover the seven common, harmful parasites that affect dogs inside and out by preventing ticks and multiple stages of the flea lifecycle, including eggs and adult fleas, as well as treating and controlling all common intestinal parasites, including roundworms, hookworms, whipworms and tapeworms and preventing heartworm disease.

Merck, a leading global biopharmaceutical company, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA, is the global animal health business unit of Merck.

The Baker Botts antitrust team was led by Antitrust Group Co-Chair Stephen Weissman (Picture), partner Michael Perry, and associate Timothy Singer.

The Paul Hastings team was led by Corporate partner David Shine, and included partners Todd Schneider, Charles Patrizia, and Eric Keller, and associates Ryan Enchelmayer, Joseph Eno, Tyler Thiret, and Matthew Tippett.

Involved fees earner: Michael Perry – Baker Botts; Timothy Singer – Baker Botts; Stephen Weissman – Baker Botts; Ryan Enchelmayer – Paul Hastings; Joseph Eno – Paul Hastings; Eric Keller – Paul Hastings; Charles Patrizia – Paul Hastings; Todd Schneider – Paul Hastings; David Shine – Paul Hastings; Tyler Thiret – Paul Hastings; Matthew Tippett – Paul Hastings;

Law Firms: Baker Botts; Paul Hastings;

Clients: Merck Animal Health;


Author: Ambrogio Visconti